Pharmacotherapy for treatment of retinal vein occlusion

Bibliography

• Coscas G, Loewenstein A, Augustin A, et al. Management of retinal vein occlusion: consensus document. Ophthalmologica 2011;226:4-28
   PubMed Web of Science ®Google Scholar
• Golan S, Fisher N, Lowenstein A. Current treatment of retinal vein occlusion. Eur Ophthalmic Rev 2011;5:62-8
   Google Scholar
• Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ 2012;344:e499
   Google Scholar
• Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;1172:313-19
   Google Scholar
• Klein R, Klein BEK, Moss SE, et al. The epidemiology of retinal vein occlusion: the beaver dam eye study. Trans Am Ophthalmol Soc 2000;98:133-43
   PubMedGoogle Scholar
• Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion: the beaver dam eye study. Arch Ophthalmol 2008;126:513-18
   PubMed Web of Science ®Google Scholar
• Frangieh GT, Green WR, Barraquer-Soers E, et al. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol 1982;100:1132-40
   PubMedGoogle Scholar
• Haymore JG, Mejico LJ. Retinal vascular occlusion syndromes. Int Opthalmol Clin 2009;49:63-79
   PubMedGoogle Scholar
• Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010;8:1886-94
   PubMed Web of Science ®Google Scholar
• Justis P, Fekrat E, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011;56:281-99
   Google Scholar
• Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010;4:809-16
   PubMedGoogle Scholar
• Deobhakta A, Chang LK. Inflammation in retinal vein occlusion. Int J Inflam 2013;2013:438412
   PubMedGoogle Scholar
• The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82
   PubMed Web of Science ®Google Scholar
• Wong TY, Scott IU. Retinal-vein occlusion. N Engl J Med 2010;363:2135-44
   PubMed Web of Science ®Google Scholar
• Branch Vein Occlusion Study Group: argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol 1986;104:34-41
   PubMedGoogle Scholar
• Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 2008;27:622-47
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-9
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-9
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-602
   PubMed Web of Science ®Google Scholar
• Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802-9
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014;121:209-19
   PubMed Web of Science ®Google Scholar
• Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high- affinity blockers of cytokine action. Nat Med 2003;9:47-52
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-8
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer D, Nguyen QD, et al. CLEAR- IT 2 Investigators: the 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor Trap-Eye dosed as needed after 12-week fixed dosing. Ophthalmology 2011;118:1098-106
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8
   PubMed Web of Science ®Google Scholar
• Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012;119:1024-32
   PubMed Web of Science ®Google Scholar
• Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-37
   PubMed Web of Science ®Google Scholar
• Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS Study. Ophthalmology 2014;121:1414-20
   PubMed Web of Science ®Google Scholar
• Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013;97:278-84
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Holz FG, Roider J, et al. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: one-Year Results of the Phase 3 GALILEO Study. Ophthalmology 2014;121:202-8
   PubMed Web of Science ®Google Scholar
• Regeneron reports positive phase 3 data for Eylea (aflibercept) injection in macular edema following branch retinal vein occlusion. Tarrytown, NY; Regeneron. 2013. Available from: http://investor.regeneron.com/releasedetail.cfm?ReleaseID=798553 [Last accessed 14 July 2014]
   Google Scholar
• Wu L, Martínez-Castellanos MA, Quiroz- Mercado H; Pan-American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizu- mab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACO- RES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7
   PubMed Web of Science ®Google Scholar
• Iturralde D, Spaide RF, Meyerle CB. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-84
   PubMed Web of Science ®Google Scholar
• Epstein DL, Algvere PV, von Wendt G, et al. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012;119:2587-91
   PubMed Web of Science ®Google Scholar
• Yilmaz T, Cordero-Coma M. Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol 2012;250:787-93
   Google Scholar
• Hikichi T, Higuchi M, Matsushita T, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2014;98:195-9
   PubMed Web of Science ®Google Scholar
• Sarao V, Veritti D, Boscia F, et al. Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal 2014;2014:989501
   PubMedGoogle Scholar
• Hou J, Tao Y, Jiang YR, et al. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J 2009;122:2695-9
   Web of Science ®Google Scholar
• Ip MS, Scott IU, Van Veldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14
   PubMed Web of Science ®Google Scholar
• Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion:the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-49
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Twelve-month study results. Ophthalmology 2011;118:2453-60
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Haller JA, Bandello F, et al. Onset and duration of visual acuity improvement after dexamethasone intravitreal with macular edema due to vein occlusion. Retina 2014. [Epub ahead of print]
   Google Scholar
• Querques G, Triolo G, Casalino G, et al. Retinal Venous Occlusions: diagnosis and Choice of Treatments. Ophthalmic Res 2013;49:215-22
   Google Scholar
• Riese J, Loukopoulos V, Meier C, et al. Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1671-6
   PubMed Web of Science ®Google Scholar
• Wang HY, Li X, Wang YS, et al. Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion. Int J Ophthalmol 2011;4:89-94
   Google Scholar
• Parodi MB, Iacono P, Ravalico G. Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol 2008;92:1046-50
   PubMed Web of Science ®Google Scholar
• Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol 2014;98:i11-16
   PubMed Web of Science ®Google Scholar
• Yeh WS, Haller JA, Lanzetta P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012;119:1190-8
   PubMed Web of Science ®Google Scholar
• Thach AB, Yau L, Hoang C, et al. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 2014;121:1059-66
   PubMed Web of Science ®Google Scholar
• Clinical trial of autologous intravitreal bone-marrow CD34+ stem cells for retinopathy. Available from: http://clinicaltrials.gov/show/NCT01736059 [Last accessed 14 July 2014]
   Google Scholar